<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND OBJECTIVES: <z:hpo ids='HP_0011010'>Chronic</z:hpo> myelomonocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e>) is a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> that has been associated with the expression of platelet-derived growth factor b receptor (PDGFRbeta) fusion proteins, namely <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta </plain></SENT>
<SENT sid="1" pm="."><plain>These fusion proteins possess a constitutive PDGFRbeta tyrosine kinase activity, leading to aberrant PDGFRbeta signaling and cellular transformation </plain></SENT>
<SENT sid="2" pm="."><plain>The expression of PDGFRbeta fusions in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> could have therapeutic relevance, as PDGFRb is inhibited by the selective <z:chebi fb="0" ids="38637">tyrosine kinase inhibitor</z:chebi>, <z:chebi fb="0" ids="45783">imatinib</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Here, we investigated the possibility of employing <z:chebi fb="0" ids="45783">imatinib</z:chebi> to treat <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>DESIGN AND METHODS: We assessed the effect of <z:chebi fb="0" ids="45783">imatinib</z:chebi> on <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta transformed cells in terms of proliferation, by trypan blue exclusion and 3H-<z:chebi fb="0" ids="17748">thymidine</z:chebi> uptake, and <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta autophosphorylation by anti-phosphotyrosine immunoblotting </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta expression in mononuclear cells from the peripheral blood of 27 clinically diagnosed <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> patients was determined by reverse transcriptase-polymerase chain reaction </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: <z:chebi fb="0" ids="45783">Imatinib</z:chebi> potently inhibited the proliferation of <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta transformed cells (IC50=7.5 nM), and <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta kinase activity </plain></SENT>
<SENT sid="7" pm="."><plain>However, <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta expression was detected in only 1 of 27 CMML patients (4%, confidence intervals: 0-13%) </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, another PDGFRbeta fusion protein, Hip1/PDGFRbeta, had a similarly low incidence in the same samples: 1 of 25 (4%, confidence intervals: 0-14%) </plain></SENT>
<SENT sid="9" pm="."><plain>INTERPRETATION AND CONCLUSIONS: Although <z:chebi fb="0" ids="45783">imatinib</z:chebi> represents an attractive therapeutic agent for <z:hpo ids='HP_0002664'>neoplasias</z:hpo> associated with abnormal PDGFRbeta signaling, the low frequency of the <z:chebi fb="18" ids="30182">TEL</z:chebi>/PDGFRbeta and Hip1/PDGFRbeta fusion proteins in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> suggests that its application to this disease maybe limited </plain></SENT>
<SENT sid="10" pm="."><plain>Detection of PDGFRbeta fusion genes in individual patients is necessary in order to employ this drug rationally in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> </plain></SENT>
</text></document>